← Back to Screener
Kymera Therapeutics, Inc. Common Stock (KYMR)
Price$78.47
Value ScoreD
Growth ScoreC
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)10.05%
Price vs S&P 500 (4W)-4.09%
VGM Score43.55
Market Capitalization$6.70B
All Metrics
Book Value / Share (Quarterly)$18.73
P/TBV (Annual)2.26x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-5.75%
Cash Flow / Share (Quarterly)$-2.97
Price vs S&P 500 (YTD)-6.29%
Net Profit Margin (TTM)-611.96%
EPS (TTM)$-3.57
10-Day Avg Trading Volume0.49M
EPS Excl Extra (TTM)$-3.57
Revenue Growth (5Y)2.87%
EPS (Annual)$-3.69
ROI (Annual)-19.67%
Net Profit Margin (5Y Avg)-384.96%
Cash / Share (Quarterly)$7.92
Revenue Growth QoQ (YoY)55.50%
ROA (Last FY)-17.86%
Revenue Growth TTM (YoY)-12.58%
EBITD / Share (TTM)$-3.95
ROE (5Y Avg)-27.42%
Operating Margin (TTM)-697.67%
Cash Flow / Share (Annual)$-2.88
P/B Ratio4.35x
P/B Ratio (Quarterly)4.42x
Net Income / Employee (Annual)$-1,230,600
EV / Revenue (TTM)127.37x
Net Interest Coverage (TTM)-1072.50x
ROA (TTM)-22.32%
EPS Incl Extra (Annual)$-3.69
Current Ratio (Annual)10.47x
Quick Ratio (Quarterly)10.39x
3-Month Avg Trading Volume0.65M
52-Week Price Return169.16%
Revenue / Employee (TTM)$203,500
Tangible BV / Share (Quarterly)$7.13
P/S Ratio (Annual)170.80x
Asset Turnover (Annual)0.02x
52-Week High$103.00
Operating Margin (5Y Avg)-427.98%
EPS Excl Extra (Annual)$-3.69
CapEx CAGR (5Y)-30.75%
26-Week Price Return25.98%
Quick Ratio (Annual)10.19x
13-Week Price Return-14.32%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)10.81x
Enterprise Value$6.56B
Revenue / Share Growth (5Y)-9.51%
Asset Turnover (TTM)0.04x
Book Value / Share Growth (5Y)24.94%
Revenue / Employee (Annual)$155,000
Pretax Margin (Annual)-794.04%
Cash / Share (Annual)$10.43
3-Month Return Std Dev39.25%
Net Income / Employee (TTM)$-1,245,100
ROE (Last FY)-19.71%
EPS Basic Excl Extra (Annual)$-3.69
Receivables Turnover (TTM)66.41x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-3.57
Receivables Turnover (Annual)4.78x
ROI (TTM)-24.95%
P/S Ratio (TTM)130.11x
Pretax Margin (5Y Avg)-384.96%
Revenue / Share (Annual)$0.46
Tangible BV / Share (Annual)$8.91
Price vs S&P 500 (52W)140.95%
Year-to-Date Return4.64%
5-Day Price Return3.21%
EPS Normalized (Annual)$-3.69
ROA (5Y Avg)-21.70%
Net Profit Margin (Annual)-794.04%
Month-to-Date Return0.43%
Cash Flow / Share (TTM)$-2.82
EBITD / Share (Annual)$-4.04
Operating Margin (Annual)-891.07%
LT Debt / Equity (Annual)0.25x
ROI (5Y Avg)-27.28%
LT Debt / Equity (Quarterly)0.16x
EPS Basic Excl Extra (TTM)$-3.57
P/TBV (Quarterly)2.80x
P/B Ratio (Annual)3.89x
Pretax Margin (TTM)-611.96%
Book Value / Share (Annual)$19.42
Price vs S&P 500 (13W)-24.07%
Beta2.03x
P/FCF (Annual)84.75x
Revenue / Share (TTM)$0.53
ROE (TTM)-25.02%
52-Week Low$28.50
vGradeD
gGradeC
mGradeB
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.71est. -0.90
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.31
4.31
4.31
4.30
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
KYMRKymera Therapeutics, Inc. Common Stock | D | C | B | $78.47 |
| AMGNAmgen Inc | C | C | C | $329.13 |
| GILDGilead Sciences Inc | C | B | C | $131.10 |
| ARGXargenx SE American Depositary Shares | D | A | C | $836.09 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $163.68 |
| BIIBBiogen Inc. Common Stock | B | D | B | $192.23 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.70 |
| MRNAModerna, Inc. Common Stock | C | B | B | $46.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $161.00 |
| EXELExelixis Inc | C | B | B | $50.28 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $298.10 |
About
Kymera Therapeutics is a clinical-stage biopharmaceutical company developing novel small molecule medicines targeting STAT6, TYK2, and IRAK4—proteins with known disease-causing biology that remain undrugged or inadequately treated with existing therapies. The company uses proprietary technologies to overcome limitations that have previously prevented effective drug development against these targets. Its disease-agnostic approach aims to generate a differentiated pipeline addressing multiple therapeutic areas with these validated biological targets.